Drugs / GMDTC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05908383 | Jan → Jun 2023 | cadmium poisoning | Jianersheng (Zhuhai) Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GMDTC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05908383 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT05908383 ↗ |